Colchicine May Interfere With the Efficacy of the Adenoviral Vector–Based Vaccine for COVID-19

Under the ongoing COVID-19 pandemic, vaccines have become the crucial players to reduce the spread of the infection. Among them, the ChAdOx1 nCoV-19 vaccine is an adenoviral vector vaccine with an overall efficacy of 70.4% in protection. The engineered adenovirus contains the SARS-CoV-2 spike protei...

Descripción completa

Detalles Bibliográficos
Autor principal: Lin, Cheng-Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950003/
https://www.ncbi.nlm.nih.gov/pubmed/35342313
http://dx.doi.org/10.1177/11795441221081061

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950003/
https://www.ncbi.nlm.nih.gov/pubmed/35342313
http://dx.doi.org/10.1177/11795441221081061

Ejemplares similares